Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.

Humans Oxaliplatin / therapeutic use Genome-Wide Association Study Colorectal Neoplasms / drug therapy Colonic Neoplasms / drug therapy Polymorphism, Genetic Antineoplastic Combined Chemotherapy Protocols / therapeutic use Fluorouracil Treatment Outcome
adjuvant chemotherapy colorectal cancer prognosis genome-wide association study oxaliplatin-based treatment single nucleotide polymorphism

Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 11 2023
Historique:
revised: 13 04 2023
received: 02 12 2022
accepted: 18 04 2023
pmc-release: 01 11 2024
medline: 8 9 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

We conducted the first large genome-wide association study to identify novel genetic variants that predict better (or poorer) prognosis in colorectal cancer patients receiving standard first-line oxaliplatin-based chemotherapy vs chemotherapy without oxaliplatin. We used data from two phase III trials, NCCTG N0147 and NCCTG N9741 and a population-based patient cohort, DACHS. Multivariable Cox proportional hazards models were employed, including an interaction term between each SNP and type of treatment for overall survival (OS) and progression-free survival. The analysis was performed for studies individually, and the results were combined using fixed-effect meta-analyses separately for resected stage III colon cancer (3098 patients from NCCTG N0147 and 549 patients from DACHS) and mCRC (505 patients from NCCTG N9741 and 437 patients from DACHS). We further performed gene-based analysis as well as in silico bioinformatics analysis for CRC-relevant functional genomic annotation of identified loci. In stage III colon cancer patients, a locus on chr22 (rs11912167) was associated with significantly poorer OS after oxaliplatin-based chemotherapy vs chemotherapy without oxaliplatin (P

Identifiants

DOI: 10.1002/ijc.34663 PMID: 37539667 PMC: PMC10550047
pubmed: 37539667
doi: 10.1002/ijc.34663
pmc: PMC10550047
mid: NIHMS1917332
doi:

Substances chimiques

Oxaliplatin 04ZR38536J
Fluorouracil U3P01618RT

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1623-1634

Subventions

Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189867
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA176272
Pays : United States
Organisme : NCI NIH HHS
ID : CA37404
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CA032102
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA014028
Pays : United States
Organisme : NCI NIH HHS
ID : CA35113
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA176272
Pays : United States
Organisme : NCI NIH HHS
ID : CA31946
Pays : United States
Organisme : NCI NIH HHS
ID : CA49957
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA035272
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CA038926
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA038926
Pays : United States
Organisme : NCI NIH HHS
ID : CA35103
Pays : United States
Organisme : NIH HHS
ID : U10CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : CA21115
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA049957
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA025224
Pays : United States
Organisme : NCI NIH HHS
ID : CA35272
Pays : United States
Organisme : NCI NIH HHS
ID : CA114740
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA077202
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA021115
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA031946
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA037404
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA114740
Pays : United States
Organisme : NCI NIH HHS
ID : CA189867
Pays : United States
Organisme : NCI NIH HHS
ID : CA25224
Pays : United States
Organisme : NIH HHS
ID : U10CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA032102
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA035113
Pays : United States
Organisme : NCI NIH HHS
ID : CA32102
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : CA14028
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA035103
Pays : United States

Informations de copyright

© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

PLoS Comput Biol. 2015 Apr 17;11(4):e1004219
pubmed: 25885710
J Cancer. 2017 Sep 30;8(17):3555-3566
pubmed: 29151941
Bioinformatics. 2014 Apr 1;30(7):1003-5
pubmed: 24227676
Eur J Cancer. 2015 Sep;51(14):1927-36
pubmed: 26188850
Cell Mol Gastroenterol Hepatol. 2021;12(1):181-197
pubmed: 33601062
Cancers (Basel). 2020 Apr 29;12(5):
pubmed: 32365581
N Engl J Med. 2004 Jun 3;350(23):2343-51
pubmed: 15175436
Oncologist. 2004;9(1):8-12
pubmed: 14755010
J Clin Oncol. 2010 Nov 1;28(31):4697-705
pubmed: 20921465
Gastroenterology. 2014 Mar;146(3):709-17
pubmed: 24012982
J Clin Oncol. 2008 Apr 20;26(12):2013-9
pubmed: 18421054
G3 (Bethesda). 2011 Nov;1(6):457-70
pubmed: 22384356
Gastroenterology. 2013 Apr;144(4):799-807.e24
pubmed: 23266556
Clin Cancer Res. 2021 Feb 15;27(4):1174-1183
pubmed: 33293373
J Clin Oncol. 2004 Jan 1;22(1):23-30
pubmed: 14665611
Int J Cancer. 2018 Feb 15;142(4):792-804
pubmed: 29044515
Lancet Oncol. 2005 May;6(5):322-7
pubmed: 15863380
Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):352-361
pubmed: 34862210
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
Nucleic Acids Res. 2020 Jan 8;48(D1):D504-D510
pubmed: 31665520
Clin Epidemiol. 2018 Jan 19;10:143-152
pubmed: 29403313
Clin Cancer Res. 2021 Jan 1;27(1):267-275
pubmed: 32958699
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Nucleic Acids Res. 2017 Jan 4;45(D1):D139-D144
pubmed: 27899579
Nat Commun. 2017 Feb 07;8:14400
pubmed: 28169291
Ann Intern Med. 2011 Jan 4;154(1):22-30
pubmed: 21200035
J BUON. 2020 Sep-Oct;25(5):2205-2214
pubmed: 33277837
Oncol Lett. 2019 Jun;17(6):5572-5580
pubmed: 31186779
Gastroenterology. 2009 Jul;137(1):176-87
pubmed: 19303019
Genome Med. 2014 Oct 28;6(10):85
pubmed: 25473424
JAMA. 2012 Apr 4;307(13):1383-93
pubmed: 22474202
Bioinformatics. 2010 Sep 15;26(18):2336-7
pubmed: 20634204

Auteurs

Hanla A Park (HA)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medical Faculty, University of Heidelberg, Heidelberg, Germany.
ORCID: 0000-0001-8055-3729

Dominic Edelmann (D)

Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Federico Canzian (F)

Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID: 0000-0002-4261-4583

Petra Seibold (P)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Tabitha A Harrison (TA)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Xinwei Hua (X)

Department of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Department of Cardiology, Peking University Third Hospital, Peking University, Beijing, China.

Qian Shi (Q)

Department of Quantitative Science, Mayo Clinic, Rochester, Minnesota, USA.

Allison Silverman (A)

Epidemiology Program, Fred Hutchinson Research Cancer Research Center, Seattle, Washington, USA.

Axel Benner (A)

Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Angelica Macauda (A)

Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID: 0000-0001-9820-5079

Martin Schneider (M)

Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.

Richard M Goldberg (RM)

West Virginia University Cancer Institute, Morgantown, West Virginia, USA.

Steven R Alberts (SR)

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Michael Hoffmeister (M)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID: 0000-0002-8307-3197

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Andrew T Chan (AT)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Ulrike Peters (U)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
School of Public Health, University of Washington, Seattle, Washington, USA.

Polly A Newcomb (PA)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
School of Public Health, University of Washington, Seattle, Washington, USA.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Genome-wide study of genetic polymorphisms...
questionsmedicales.fr › Composés chimiques organiques › Complexes de coordination › Oxaliplatine › Genome-wide study of genetic polymorphisms...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Épidémiologie moléculaire › Étude d'association pangénomique › Genome-wide study of genetic polymorphisms...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Genome-wide study of genetic polymorphisms...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Tumeurs de l'intestin › Tumeurs du côlon › Genome-wide study of genetic polymorphisms...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Genome-wide study of genetic polymorphisms...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Genome-wide study of genetic polymorphisms...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Uracile › Fluorouracil › Genome-wide study of genetic polymorphisms...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Genome-wide study of genetic polymorphisms...